• Lingua: Italiano
    • Italiano Italiano
    • English English

CNCCS

MENU
  • Home
  • Collezione composti chimici
    • Raccolta Composti
    • Laboratori
  • Centro malattie rare
    • Aree di Ricerca
    • Malattie Rare
    • Malattie Trascurate e della Povertà
  • Bioeconomy
    • Bioeconomy Rome Edizione 2014
    • Bioeconomy Rome Edizione 2013
    • Bioeconomy Rome Edizione 2012
    • Bioeconomy Rome Edizione 2011
  • Media
    • Stampa
    • Videos 2020
    • Video
  • Contatti
  • Lavora con Noi

Coronavirus, il vaccino è di Pomezia

8 febbraio 2020 Comments (0) Rassegna Stampa  Like

Article published on Latina OGGI – 08/02/2020

Download pdf

 Like Rassegna Stampa Coronavirus, il vaccino è di Pomezia

About the Author: info@iwebyou.it

Comments are closed.

Articoli recenti

  • «The anti-covid vaccine in pharmacies in January» Piero Di Lorenzo, President of IRBM in Pomezia (Rome): «It will cost 2-3 euros, two billion doses will be produced in a year. Italy can rest assured»
  • Covid, Minister Speranza to the Washington Post: “The Oxford-Pomezia vaccine will arrive before the others”
  • Interview with Piero Di Lorenzo. The Italian company. Enthusiasm in Rome: «But now we have to be cautious»
  • Interview with Matteo Liguori: «Everything will depend on tests on subjects at risk»
  • Covid, Minister Speranza to the Washington Post: “The Oxford-Pomezia vaccine will arrive before the others”

Contatti

Fax: +39.06.91093654
Mail: info@cnccs

CNCCS Scarl
Collezione Nazionale dei Composti Chimici e Centro Screening
Via Pontina km 30,600 – 00040 Pomezia (RM)

News

  • «The anti-covid vaccine in pharmacies in January» Piero Di Lorenzo, President of IRBM in Pomezia (Rome): «It will cost 2-3 euros, two billion doses will be produced in a year. Italy can rest assured»
  • Covid, Minister Speranza to the Washington Post: “The Oxford-Pomezia vaccine will arrive before the others”
  • Interview with Piero Di Lorenzo. The Italian company. Enthusiasm in Rome: «But now we have to be cautious»
  • Interview with Matteo Liguori: «Everything will depend on tests on subjects at risk»

Partners